marketcaparena
Search

    A

    AGILENT TECHNOLOGIES, INC.

    Company overview

    Market capitalization
    $49.48B
    Employees
    18,000
    Latest publication
    2026-09-29
    About AGILENT TECHNOLOGIES, INC.

    Agilent Technologies, Inc. provides application focused solutions to the life sciences, diagnostics, and applied chemical markets worldwide. The company operates through three segments: Life Sciences and Diagnostics Markets, Agilent CrossLab, and Applied Markets. The Life Sciences and Diagnostics Markets segment offers liquid chromatography systems and components; and liquid chromatography mass spectrometry systems. This segment is also involved in the genomics, contract development and manufacturing organization, pathology, companion diagnostics, and biomolecular analysis businesses. The Agilent CrossLab segment provides various services, including repairs, parts, maintenance, installations, training, compliance support, software as a service, asset management, consulting, and other custom services. This segment also offers consumables, including gas chromatography and liquid chromatography columns, sample preparation products, custom chemistries, and various laboratory supplies; software and informatics solutions comprising software for instrument control, data acquisition, data analysis, secure storage of results, and laboratory information and workflow management; and OpenLab laboratory software, an open software platform that enables customers to capture, analyze, and share scientific data throughout the lab and across the enterprise. In addition, it provides automated sample preparation solutions, such as liquid handling, plate management, consumables, and scheduling software. The Applied Markets segment offers products in the areas of gas chromatography, mass spectrometry, spectroscopy, vacuum technology, and remarketed instruments. It markets its products through direct sales, distributors, resellers, manufacturer's representatives, and electronic commerce. Agilent Technologies, Inc. was incorporated in 1999 and is headquartered in Santa Clara, California.

    Company website

    Financial statements

    Income Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ3 20262026-07-31 · USDQ2 20262026-04-30 · USDQ1 20262026-01-31 · USDQ4 20252025-10-31 · USDQ3 20252025-07-31 · USDQ2 20252025-04-30 · USDQ1 20252025-01-31 · USDQ4 20242024-10-31 · USD
    Total Revenue1,878,000,000USD1,835,000,000USD1,798,000,000USD1,861,000,000USD1,738,000,000USD1,668,000,000USD1,681,000,000USD1,701,000,000USD
    Cost Of Revenue836,000,000USD845,000,000USD852,000,000USD—850,000,000USD802,000,000USD782,000,000USD—
    Gross Profit1,042,000,000USD990,000,000USD946,000,000USD—888,000,000USD866,000,000USD899,000,000USD—
    Research Development123,000,000USD126,000,000USD117,000,000USD119,000,000USD111,000,000USD112,000,000USD113,000,000USD111,000,000USD
    Selling General Administrative475,000,000USD465,000,000USD476,000,000USD428,000,000USD417,000,000USD454,000,000USD410,000,000USD397,000,000USD
    Total Operating Expenses598,000,000USD591,000,000USD593,000,000USD—528,000,000USD566,000,000USD523,000,000USD—
    Operating Income444,000,000USD399,000,000USD353,000,000USD443,000,000USD360,000,000USD300,000,000USD376,000,000USD408,000,000USD
    Total Other Income Expense Net0USD9,000,000USD11,000,000USD—6,000,000USD-40,000,000USD-9,000,000USD—
    Interest Income15,000,000USD13,000,000USD15,000,000USD—16,000,000USD14,000,000USD15,000,000USD—
    Interest Expense29,000,000USD25,000,000USD25,000,000USD—28,000,000USD29,000,000USD28,000,000USD—
    Income Before Tax444,000,000USD408,000,000USD364,000,000USD442,000,000USD366,000,000USD260,000,000USD367,000,000USD401,000,000USD
    Income Tax Expense82,000,000USD69,000,000USD59,000,000USD132,000,000USD30,000,000USD45,000,000USD49,000,000USD—
    Net Income362,000,000USD339,000,000USD305,000,000USD434,000,000USD336,000,000USD215,000,000USD318,000,000USD351,000,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosurePreliminaryDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosurePreliminary

    Income Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-10-31 · USDFY 20242024-10-31 · USDFY 20232023-10-31 · USDFY 20222022-10-31 · USDFY 20212021-10-31 · USDFY 20202020-10-31 · USDFY 20192019-10-31 · USDFY 20182018-10-31 · USD
    Total Revenue6,948,000,000USD6,510,000,000USD6,833,000,000USD6,848,000,000USD6,319,000,000USD5,339,000,000USD5,163,000,000USD4,914,000,000USD
    Cost Of Revenue3,305,000,000USD2,975,000,000USD3,368,000,000USD3,126,000,000USD2,912,000,000USD2,502,000,000USD2,358,000,000USD2,227,000,000USD
    Gross Profit3,643,000,000USD3,535,000,000USD3,465,000,000USD3,722,000,000USD3,407,000,000USD2,837,000,000USD2,805,000,000USD2,687,000,000USD
    Research Development455,000,000USD479,000,000USD481,000,000USD467,000,000USD441,000,000USD495,000,000USD404,000,000USD385,000,000USD
    Selling General Administrative1,709,000,000USD1,568,000,000USD1,634,000,000USD1,637,000,000USD1,619,000,000USD1,496,000,000USD1,460,000,000USD1,374,000,000USD
    Total Operating Expenses2,164,000,000USD2,047,000,000USD2,115,000,000USD2,104,000,000USD2,060,000,000USD1,991,000,000USD1,864,000,000USD1,759,000,000USD
    Operating Income1,479,000,000USD1,488,000,000USD1,350,000,000USD1,618,000,000USD1,347,000,000USD846,000,000USD941,000,000USD928,000,000USD
    Total Other Income Expense Net-44,000,000USD33,000,000USD-11,000,000USD-114,000,000USD13,000,000USD-4,000,000USD-22,000,000USD18,000,000USD
    Interest Income62,000,000USD80,000,000USD51,000,000USD9,000,000USD2,000,000USD8,000,000USD36,000,000USD38,000,000USD
    Interest Expense112,000,000USD96,000,000USD95,000,000USD84,000,000USD81,000,000USD78,000,000USD74,000,000USD75,000,000USD
    Income Before Tax1,435,000,000USD1,521,000,000USD1,339,000,000USD1,504,000,000USD1,360,000,000USD842,000,000USD919,000,000USD946,000,000USD
    Income Tax Expense132,000,000USD232,000,000USD99,000,000USD250,000,000USD150,000,000USD123,000,000USD-152,000,000USD630,000,000USD
    Net Income1,303,000,000USD1,289,000,000USD1,240,000,000USD1,254,000,000USD1,210,000,000USD719,000,000USD1,071,000,000USD316,000,000USD
    Equity Method Income Loss———————0USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinal

    Balance sheet Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ3 20262026-07-31 · USDQ2 20262026-04-30 · USDQ1 20262026-01-31 · USDQ4 20252025-10-31 · USDQ3 20252025-07-31 · USDQ2 20252025-04-30 · USDQ1 20252025-01-31 · USDQ4 20242024-10-31 · USD
    Total current liabilities2,289,000,000USD———————
    Total liabilities6,604,000,000USD———————
    Inventory1,117,000,000USD1,089,000,000USD1,059,000,000USD1,025,000,000USD1,014,000,000USD991,000,000USD997,000,000USD972,000,000USD
    Total assets13,967,000,000USD———————
    Additional paid in capital5,681,000,000USD———————
    Short term debt304,000,000USD———————
    Retirement and postretirement benefits128,000,000USD———————
    Other current assets340,000,000USD———————
    Accounts payable608,000,000USD———————
    Total liabilities and stockholders' equity13,967,000,000USD———————
    Property, plant and equipment, net2,134,000,000USD———————
    Accounts receivable, net1,478,000,000USD———————
    Long term debt3,645,000,000USD———————
    Accumulated other comprehensive loss-233,000,000USD———————
    Other long term liabilities542,000,000USD———————
    Other assets1,074,000,000USD———————
    Retained earnings1,912,000,000USD———————
    Common stock; $0.01 par value; 2,000,000,000 shares authorized; 281,965,813 shares at July 31, 2026 and 283,054,377 shares at October 31, 2025 issued and outstanding3,000,000USD———————
    Long term investments130,000,000USD———————
    Cash and cash equivalents1,758,000,000USD———————
    Goodwill5,030,000,000USD4,484,000,000USD4,484,000,000USD4,473,000,000USD4,475,000,000USD4,474,000,000USD4,429,000,000USD4,477,000,000USD
    Other intangible assets, net906,000,000USD———————
    Other accrued liabilities314,000,000USD———————
    Deferred revenue640,000,000USD———————
    Total stockholders' equity7,363,000,000USD———————
    Total current assets4,693,000,000USD———————
    Employee compensation and benefits423,000,000USD———————
    Total Assets—13,065,000,000USD12,813,000,000USD12,727,000,000USD12,226,000,000USD12,158,000,000USD11,914,000,000USD11,846,000,000USD
    Cash And Equivalents—1,807,000,000USD1,758,000,000USD1,789,000,000USD1,535,000,000USD1,486,000,000USD1,467,000,000USD1,329,000,000USD
    Long Term Investments—136,000,000USD135,000,000USD133,000,000USD133,000,000USD135,000,000USD173,000,000USD175,000,000USD
    Total Current Assets—4,763,000,000USD4,615,000,000USD4,594,000,000USD4,253,000,000USD4,208,000,000USD4,107,000,000USD3,959,000,000USD
    Other Current Assets—369,000,000USD277,000,000USD293,000,000USD322,000,000USD365,000,000USD315,000,000USD334,000,000USD
    Other Non Current Assets—1,176,000,000USD1,075,000,000USD1,059,000,000USD930,000,000USD934,000,000USD875,000,000USD910,000,000USD
    Total Liabilities—5,943,000,000USD5,905,000,000USD5,986,000,000USD5,856,000,000USD6,022,000,000USD5,887,000,000USD5,948,000,000USD
    Total Current Liabilities—2,269,000,000USD2,234,000,000USD2,347,000,000USD1,892,000,000USD2,012,000,000USD1,869,000,000USD1,895,000,000USD
    Other Non Current Liabilities—496,000,000USD491,000,000USD463,000,000USD495,000,000USD535,000,000USD551,000,000USD578,000,000USD
    Total Stockholder Equity—7,122,000,000USD6,908,000,000USD6,741,000,000USD6,370,000,000USD6,136,000,000USD6,027,000,000USD5,898,000,000USD
    Total Equity Including Noncontrolling Interest—-202,000,000USD-184,000,000USD-226,000,000USD-283,000,000USD-280,000,000USD6,027,000,000USD5,898,000,000USD
    Deferred Revenue—665,000,000USD682,000,000USD624,000,000USD620,000,000USD628,000,000USD612,000,000USD544,000,000USD
    Net Receivables—1,498,000,000USD1,521,000,000USD1,487,000,000USD1,382,000,000USD1,366,000,000USD1,328,000,000USD1,324,000,000USD
    Property Plant Equipment Net—2,280,000,000USD2,267,000,000USD2,206,000,000USD2,145,000,000USD2,094,000,000USD1,988,000,000USD1,955,000,000USD
    Intangible Assets—407,000,000USD426,000,000USD445,000,000USD469,000,000USD495,000,000USD514,000,000USD547,000,000USD
    Accounts Payable—615,000,000USD602,000,000USD570,000,000USD530,000,000USD517,000,000USD547,000,000USD540,000,000USD
    Common Stock—3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD
    Retained Earnings—1,692,000,000USD1,484,000,000USD1,389,000,000USD1,102,000,000USD912,000,000USD916,000,000USD750,000,000USD
    Accumulated Other Comprehensive Income—-202,000,000USD-184,000,000USD-226,000,000USD-283,000,000USD-280,000,000USD-381,000,000USD-305,000,000USD
    Cash And Short Term Investments———1,789,000,000USD———1,329,000,000USD
    Short Term Investments———0USD———0USD
    Other Current Liabilities———406,000,000USD———398,000,000USD
    Short Term Debt———44,000,000USD———42,000,000USD
    SourceDisclosureVerifiedDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinal

    Balance sheet Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-10-31 · USDFY 20242024-10-31 · USDFY 20232023-10-31 · USDFY 20222022-10-31 · USDFY 20212021-10-31 · USDFY 20202020-10-31 · USDFY 20192019-10-31 · USDFY 20182018-10-31 · USD
    Total Assets12,727,000,000USD11,846,000,000USD10,763,000,000USD10,532,000,000USD10,705,000,000USD9,627,000,000USD9,452,000,000USD8,541,000,000USD
    Cash And Equivalents1,789,000,000USD1,329,000,000USD1,590,000,000USD1,053,000,000USD1,484,000,000USD1,441,000,000USD1,382,000,000USD2,247,000,000USD
    Cash And Short Term Investments1,789,000,000USD1,329,000,000USD1,590,000,000USD1,053,000,000USD1,575,000,000USD1,466,000,000USD1,407,000,000USD—
    Short Term Investments0USD0USD0USD0USD91,000,000USD25,000,000USD25,000,000USD—
    Long Term Investments133,000,000USD175,000,000USD164,000,000USD195,000,000USD185,000,000USD158,000,000USD102,000,000USD68,000,000USD
    Total Current Assets4,594,000,000USD3,959,000,000USD4,186,000,000USD3,778,000,000USD3,799,000,000USD3,415,000,000USD3,189,000,000USD3,848,000,000USD
    Other Current Assets293,000,000USD334,000,000USD274,000,000USD282,000,000USD222,000,000USD216,000,000USD198,000,000USD187,000,000USD
    Other Non Current Assets1,059,000,000USD910,000,000USD708,000,000USD686,000,000USD820,000,000USD776,000,000USD611,000,000USD339,000,000USD
    Total Liabilities5,986,000,000USD5,948,000,000USD4,918,000,000USD5,227,000,000USD5,316,000,000USD4,754,000,000USD4,704,000,000USD3,970,000,000USD
    Total Current Liabilities2,347,000,000USD1,895,000,000USD1,603,000,000USD1,861,000,000USD1,708,000,000USD1,467,000,000USD2,080,000,000USD1,171,000,000USD
    Other Current Liabilities406,000,000USD398,000,000USD309,000,000USD329,000,000USD328,000,000USD285,000,000USD440,000,000USD203,000,000USD
    Other Non Current Liabilities463,000,000USD578,000,000USD477,000,000USD536,000,000USD659,000,000USD614,000,000USD473,000,000USD761,000,000USD
    Total Stockholder Equity6,741,000,000USD5,898,000,000USD5,845,000,000USD5,305,000,000USD5,389,000,000USD4,873,000,000USD4,748,000,000USD4,567,000,000USD
    Total Equity Including Noncontrolling Interest-226,000,000USD5,898,000,000USD5,845,000,000USD5,305,000,000USD5,389,000,000USD4,873,000,000USD4,748,000,000USD4,571,000,000USD
    Deferred Revenue624,000,000USD544,000,000USD505,000,000USD461,000,000USD441,000,000USD386,000,000USD336,000,000USD324,000,000USD
    Net Receivables1,487,000,000USD1,324,000,000USD1,291,000,000USD1,405,000,000USD1,172,000,000USD1,038,000,000USD930,000,000USD776,000,000USD
    Inventory1,025,000,000USD972,000,000USD1,031,000,000USD1,038,000,000USD830,000,000USD720,000,000USD679,000,000USD638,000,000USD
    Property Plant Equipment Net2,206,000,000USD1,955,000,000USD1,424,000,000USD1,250,000,000USD1,123,000,000USD1,020,000,000USD1,045,000,000USD822,000,000USD
    Goodwill4,473,000,000USD4,477,000,000USD3,960,000,000USD3,952,000,000USD3,975,000,000USD3,602,000,000USD3,593,000,000USD2,973,000,000USD
    Intangible Assets445,000,000USD547,000,000USD475,000,000USD821,000,000USD981,000,000USD831,000,000USD1,107,000,000USD491,000,000USD
    Accounts Payable570,000,000USD540,000,000USD418,000,000USD580,000,000USD446,000,000USD354,000,000USD354,000,000USD340,000,000USD
    Short Term Debt44,000,000USD42,000,000USD46,000,000USD51,000,000USD52,000,000USD———
    Common Stock3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD3,000,000USD
    Retained Earnings1,389,000,000USD750,000,000USD782,000,000USD324,000,000USD348,000,000USD81,000,000USD-18,000,000USD-336,000,000USD
    Accumulated Other Comprehensive Income-226,000,000USD-305,000,000USD-327,000,000USD-347,000,000USD-282,000,000USD-522,000,000USD-514,000,000USD-408,000,000USD
    Long Term Debt————2,729,000,000USD2,284,000,000USD1,791,000,000USD1,799,000,000USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinal

    Cash flow YTD

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ3 20262026-07-31 · USDQ2 20262026-04-30 · USDQ3 20252025-07-31 · USDQ2 20252025-04-30 · USDQ3 20242024-07-31 · USDQ2 20242024-04-30 · USDQ3 20232023-07-31 · USDQ2 20232023-04-30 · USD
    Net change in property, plant and equipment included in accounts payable and accrued liabilities increase (decrease)-9,000,000USD———————
    Cash, cash equivalents and restricted cash at end of period1,760,000,000USD———————
    Other non cash (income) expense, net-12,000,000USD———————
    Other assets and liabilities-295,000,000USD———————
    Income tax paid, net of refunds received376,000,000USD———————
    Depreciation and amortization200,000,000USD———————
    Payments for repurchase of common stock-295,000,000USD———————
    Payments of debt issuance costs-5,000,000USD———————
    Deferred taxes expense (benefit)77,000,000USD———————
    Net cash provided by operating activities1,064,000,000USD———————
    Net income1,006,000,000USD———————
    Excise tax on share repurchases, accrued but not paid2,000,000USD———————
    Share based compensation105,000,000USD———————
    Employee compensation and benefits-25,000,000USD———————
    Net cash used in investing activities-1,202,000,000USD———————
    Inventory-110,000,000USD———————
    Proceeds from issuance of long term debt600,000,000USD———————
    Interest payments, net of capitalized interest47,000,000USD———————
    Net (gain) loss on equity securities-2,000,000USD———————
    Net cash provided by (used in) financing activities105,000,000USD———————
    Payments in exchange for convertible note-3,000,000USD———————
    Payments of dividends-216,000,000USD———————
    Accounts payable41,000,000USD———————
    Net increase (decrease) in cash, cash equivalents and restricted cash-31,000,000USD———————
    Excess and obsolete inventory related charges35,000,000USD———————
    Payments of finance lease-4,000,000USD———————
    Effect of exchange rate movements2,000,000USD———————
    Payments to acquire businesses and intangible assets, net of cash acquired-950,000,000USD———————
    Payments of taxes related to net share settlement of equity awards-31,000,000USD———————
    Repayments of long term debt-4,000,000USD———————
    Payment of excise taxes related to repurchases of common stock-3,000,000USD———————
    Proceeds from issuance of common stock under employee stock plans63,000,000USD———————
    Payments to acquire property, plant and equipment-249,000,000USD———————
    Accounts receivable, net-16,000,000USD———————
    Depreciation—134,000,000USD217,000,000USD145,000,000USD188,000,000USD125,000,000USD209,000,000USD138,000,000USD
    Stock Based Compensation—73,000,000USD102,000,000USD70,000,000USD103,000,000USD75,000,000USD97,000,000USD68,000,000USD
    Deferred Income Tax—57,000,000USD-35,000,000USD-28,000,000USD-8,000,000USD-7,000,000USD-69,000,000USD-1,000,000USD
    Other Non Cash Items—-4,000,000USD-4,000,000USD-2,000,000USD-2,000,000USD4,000,000USD-4,000,000USD-2,000,000USD
    Change To Account Receivables—-6,000,000USD-44,000,000USD-27,000,000USD67,000,000USD44,000,000USD113,000,000USD49,000,000USD
    Change To Inventory—-85,000,000USD-72,000,000USD-41,000,000USD15,000,000USD3,000,000USD-53,000,000USD-71,000,000USD
    Change To Liabilities—43,000,000USD-13,000,000USD-27,000,000USD78,000,000USD43,000,000USD-117,000,000USD-101,000,000USD
    Change In Working Capital—-108,000,000USD-142,000,000USD-104,000,000USD87,000,000USD37,000,000USD-218,000,000USD-254,000,000USD
    Operating Cash Flow—545,000,000USD1,014,000,000USD652,000,000USD1,270,000,000USD818,000,000USD1,256,000,000USD694,000,000USD
    Capital Expenditures—-169,000,000USD-314,000,000USD-211,000,000USD-285,000,000USD-193,000,000USD-214,000,000USD-133,000,000USD
    Other Investing Activities—0USD-4,000,000USD-4,000,000USD-3,000,000USD0USD-51,000,000USD-51,000,000USD
    Unclassified Investing Cash Flow—-1,000,000USD14,000,000USD7,000,000USD-16,000,000USD-11,000,000USD-5,000,000USD3,000,000USD
    Investing Cash Flow—-170,000,000USD-304,000,000USD-208,000,000USD-304,000,000USD-204,000,000USD-270,000,000USD-181,000,000USD
    Net Debt Issuance—-5,000,000USD15,000,000USD103,000,000USD195,000,000USD-180,000,000USD20,000,000USD—
    Common Stock Issuance—32,000,000USD60,000,000USD31,000,000USD76,000,000USD43,000,000USD65,000,000USD35,000,000USD
    Net Common Stock Issuance—-246,000,000USD-368,000,000USD-279,000,000USD-842,000,000USD-256,000,000USD-548,000,000USD-212,000,000USD
    Common Dividends Paid—-144,000,000USD-212,000,000USD-141,000,000USD-206,000,000USD-138,000,000USD-199,000,000USD-133,000,000USD
    Unclassified Financing Cash Flow—-3,000,000USD-10,000,000USD-10,000,000USD——-67,000,000USD-97,000,000USD
    Financing Cash Flow—-366,000,000USD-515,000,000USD-296,000,000USD-777,000,000USD-531,000,000USD-729,000,000USD-407,000,000USD
    Effect Of Forex Changes On Cash—9,000,000USD10,000,000USD9,000,000USD0USD-2,000,000USD19,000,000USD16,000,000USD
    Change In Cash—18,000,000USD205,000,000USD157,000,000USD189,000,000USD81,000,000USD276,000,000USD122,000,000USD
    End Cash Flow—1,809,000,000USD1,537,000,000USD1,489,000,000USD1,782,000,000USD1,674,000,000USD1,332,000,000USD1,178,000,000USD
    SourceDisclosureVerifiedDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinal

    Cash flow Quarterly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricQ2 20262026-04-30 · USDQ1 20262026-01-31 · USDQ4 20252025-10-31 · USDQ3 20252025-07-31 · USDQ2 20252025-04-30 · USDQ1 20252025-01-31 · USDQ4 20242024-10-31 · USDQ3 20242024-07-31 · USD
    Net Income339,000,000USD—434,000,000USD336,000,000USD215,000,000USD—351,000,000USD282,000,000USD
    Depreciation67,000,000USD67,000,000USD288,000,000USD217,000,000USD145,000,000USD72,000,000USD257,000,000USD188,000,000USD
    Stock Based Compensation32,000,000USD41,000,000USD128,000,000USD102,000,000USD70,000,000USD40,000,000USD129,000,000USD103,000,000USD
    Other Non Cash Items117,000,000USD-2,000,000USD———0USD——
    Change To Account Receivables12,000,000USD-18,000,000USD———-30,000,000USD——
    Change To Inventory-46,000,000USD-39,000,000USD———-40,000,000USD——
    Change In Working Capital-211,000,000USD-170,000,000USD———-149,000,000USD——
    Total Cash From Operating Activities277,000,000USD———————
    Capital Expenditures93,000,000USD-93,000,000USD———-97,000,000USD——
    Free Cash Flow370,000,000USD———————
    Total Cashflows From Investing Activities-77,000,000USD———————
    Net Borrowings-3,000,000USD———————
    Total Cash From Financing Activities-144,000,000USD———————
    Dividends Paid-72,000,000USD———————
    Sale Purchase Of Stock-65,000,000USD———————
    Change In Cash49,000,000USD-31,000,000USD———138,000,000USD—189,000,000USD
    Begin Period Cash Flow1,758,000,000USD———————
    End Period Cash Flow1,809,000,000USD———————
    Other Cashflows From Investing Activities-170,000,000USD———————
    Other Cashflows From Financing Activities-5,000,000USD———————
    Unclassified Operating Cash Flow-67,000,000USD———————
    Deferred Income Tax—25,000,000USD———-10,000,000USD——
    Change To Liabilities—28,000,000USD———11,000,000USD——
    Operating Cash Flow—268,000,000USD1,559,000,000USD1,014,000,000USD652,000,000USD431,000,000USD1,751,000,000USD1,270,000,000USD
    Other Investing Activities—0USD———-4,000,000USD——
    Investing Cash Flow—-93,000,000USD-394,000,000USD-304,000,000USD-208,000,000USD-94,000,000USD-1,258,000,000USD-304,000,000USD
    Net Debt Issuance—-2,000,000USD———-27,000,000USD——
    Common Stock Issuance—31,000,000USD———30,000,000USD——
    Net Common Stock Issuance—-179,000,000USD———-112,000,000USD——
    Common Dividends Paid—-72,000,000USD———-71,000,000USD——
    Financing Cash Flow—-222,000,000USD-715,000,000USD-515,000,000USD-296,000,000USD-180,000,000USD-752,000,000USD-777,000,000USD
    Effect Of Forex Changes On Cash—16,000,000USD———-19,000,000USD——
    End Cash Flow—1,760,000,000USD1,791,000,000USD1,537,000,000USD1,489,000,000USD1,470,000,000USD1,332,000,000USD1,782,000,000USD
    Unclassified Investing Cash Flow—————7,000,000USD——
    SourceLegacy providerLegacyDisclosureDeterministicFinalDisclosurePreliminaryDisclosurePreliminaryDisclosurePreliminaryDisclosureDeterministicFinalDisclosurePreliminaryDisclosurePreliminary

    Cash flow Yearly

    Exact reported values; units shown beside each amount. Missing values are —.
    MetricFY 20252025-10-31 · USDFY 20242024-10-31 · USDFY 20232023-10-31 · USDFY 20222022-10-31 · USDFY 20212021-10-31 · USDFY 20202020-10-31 · USDFY 20192019-10-31 · USDFY 20182018-10-31 · USD
    Depreciation288,000,000USD257,000,000USD271,000,000USD317,000,000USD321,000,000USD308,000,000USD238,000,000USD210,000,000USD
    Stock Based Compensation128,000,000USD129,000,000USD111,000,000USD125,000,000USD110,000,000USD83,000,000USD72,000,000USD70,000,000USD
    Deferred Income Tax-130,000,000USD-64,000,000USD-56,000,000USD8,000,000USD14,000,000USD29,000,000USD-255,000,000USD-16,000,000USD
    Other Non Cash Items-5,000,000USD1,000,000USD-6,000,000USD-20,000,000USD-20,000,000USD-8,000,000USD-15,000,000USD-9,000,000USD
    Change To Account Receivables-149,000,000USD7,000,000USD132,000,000USD-321,000,000USD-128,000,000USD-107,000,000USD-106,000,000USD-65,000,000USD
    Change To Inventory-97,000,000USD34,000,000USD-33,000,000USD-248,000,000USD-136,000,000USD-68,000,000USD-36,000,000USD-83,000,000USD
    Change To Liabilities16,000,000USD103,000,000USD-171,000,000USD121,000,000USD64,000,000USD2,000,000USD29,000,000USD40,000,000USD
    Change In Working Capital-154,000,000USD123,000,000USD-191,000,000USD-459,000,000USD-88,000,000USD-144,000,000USD-90,000,000USD-77,000,000USD
    Operating Cash Flow1,559,000,000USD1,751,000,000USD1,772,000,000USD1,312,000,000USD1,485,000,000USD921,000,000USD1,021,000,000USD1,087,000,000USD
    Capital Expenditures-407,000,000USD-378,000,000USD-298,000,000USD-291,000,000USD-188,000,000USD-119,000,000USD-155,000,000USD-177,000,000USD
    Other Investing Activities-4,000,000USD-862,000,000USD-51,000,000USD-52,000,000USD-546,000,000USD0USD-1,408,000,000USD-516,000,000USD
    Unclassified Investing Cash Flow17,000,000USD-18,000,000USD39,000,000USD5,000,000USD-15,000,000USD-8,000,000USD-4,000,000USD-11,000,000USD
    Investing Cash Flow-394,000,000USD-1,258,000,000USD-310,000,000USD-338,000,000USD-749,000,000USD-147,000,000USD-1,590,000,000USD-704,000,000USD
    Net Debt Issuance-41,000,000USD637,000,000USD-35,000,000USD0USD0USD-4,000,000USD103,000,000USD-210,000,000USD
    Common Stock Issuance72,000,000USD77,000,000USD67,000,000USD58,000,000USD55,000,000USD60,000,000USD54,000,000USD56,000,000USD
    Net Common Stock Issuance-454,000,000USD-1,180,000,000USD-629,000,000USD-1,206,000,000USD-864,000,000USD-506,000,000USD-739,000,000USD-452,000,000USD
    Common Dividends Paid-282,000,000USD-274,000,000USD-265,000,000USD-250,000,000USD-236,000,000USD-222,000,000USD-206,000,000USD-191,000,000USD
    Unclassified Financing Cash Flow-10,000,000USD-12,000,000USD-68,000,000USD26,000,000USD349,000,000USD-45,000,000USD489,000,000USD—
    Financing Cash Flow-715,000,000USD-752,000,000USD-930,000,000USD-1,372,000,000USD-696,000,000USD-717,000,000USD-299,000,000USD-797,000,000USD
    Effect Of Forex Changes On Cash9,000,000USD-2,000,000USD5,000,000USD-36,000,000USD————
    Change In Cash459,000,000USD-261,000,000USD537,000,000USD-434,000,000USD43,000,000USD59,000,000USD-866,000,000USD—
    End Cash Flow1,791,000,000USD1,332,000,000USD1,593,000,000USD1,056,000,000USD1,490,000,000USD1,447,000,000USD1,388,000,000USD—
    Net Investments—————-20,000,000USD-23,000,000USD0USD
    SourceDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinalDisclosureDeterministicFinal

    Operating metrics

    No operating metrics are currently published for this company.

    Revenue breakdown

    PeriodDimensionBusiness / regionRevenueCurrencySource
    Q2 2026Quarterly · 2026-04-30GeographyAmericas764,000,000USDDisclosure
    Q2 2026Quarterly · 2026-04-30GeographyAsia Pacific553,000,000USDDisclosure
    Q2 2026Quarterly · 2026-04-30GeographyEurope518,000,000USDDisclosure
    Q2 2026Quarterly · 2026-04-30ProductInstrumentation618,000,000USDDisclosure
    Q2 2026Quarterly · 2026-04-30ProductNon Instrumentationand Other1,217,000,000USDDisclosure
    Q2 2026Quarterly · 2026-04-30SegmentAgilent Cross Lab759,000,000USDDisclosure
    Q2 2026Quarterly · 2026-04-30SegmentApplied Markets344,000,000USDDisclosure
    Q2 2026Quarterly · 2026-04-30SegmentLife Sciences And Diagnostics Markets732,000,000USDDisclosure
    Q1 2026Quarterly · 2026-01-31GeographyAmericas678,000,000USDDisclosure
    Q1 2026Quarterly · 2026-01-31GeographyAsia Pacific602,000,000USDDisclosure
    Q1 2026Quarterly · 2026-01-31GeographyEurope518,000,000USDDisclosure
    Q1 2026Quarterly · 2026-01-31ProductInstrumentation658,000,000USDDisclosure
    Q1 2026Quarterly · 2026-01-31ProductNon Instrumentationand Other1,140,000,000USDDisclosure
    Q1 2026Quarterly · 2026-01-31SegmentAgilent Cross Lab758,000,000USDDisclosure
    Q1 2026Quarterly · 2026-01-31SegmentApplied Markets361,000,000USDDisclosure
    Q1 2026Quarterly · 2026-01-31SegmentLife Sciences And Diagnostics Markets679,000,000USDDisclosure
    Q4 2025Quarterly · 2025-10-31ProductInstrumentation653,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-10-31ProductNon Instrumentationand Other1,208,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-10-31SegmentAgilent Cross Lab755,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-10-31SegmentApplied Markets351,000,000USDLegacy provider
    Q4 2025Quarterly · 2025-10-31SegmentLife Sciences And Diagnostics Markets755,000,000USDLegacy provider
    FY 2025Yearly · 2025-10-31ProductInstrumentation2,427,000,000USDDisclosure
    FY 2025Yearly · 2025-10-31ProductNon Instrumentationand Other4,521,000,000USDDisclosure
    FY 2025Yearly · 2025-10-31SegmentAgilent Cross Lab2,908,000,000USDDisclosure
    FY 2025Yearly · 2025-10-31SegmentApplied Markets1,314,000,000USDDisclosure
    FY 2025Yearly · 2025-10-31SegmentLife Sciences And Diagnostics Markets2,726,000,000USDDisclosure
    Q3 2025Quarterly · 2025-07-31GeographyAmericas683,000,000USDDisclosure
    Q3 2025Quarterly · 2025-07-31GeographyAsia Pacific563,000,000USDDisclosure
    Q3 2025Quarterly · 2025-07-31GeographyEurope492,000,000USDDisclosure
    Q3 2025Quarterly · 2025-07-31ProductInstrumentation599,000,000USDDisclosure
    Q3 2025Quarterly · 2025-07-31ProductNon Instrumentationand Other1,139,000,000USDDisclosure
    Q3 2025Quarterly · 2025-07-31SegmentAgilent Cross Lab744,000,000USDDisclosure
    Q3 2025Quarterly · 2025-07-31SegmentApplied Markets324,000,000USDDisclosure
    Q3 2025Quarterly · 2025-07-31SegmentLife Sciences And Diagnostics Markets670,000,000USDDisclosure
    Q2 2025Quarterly · 2025-04-30GeographyAmericas678,000,000USDDisclosure
    Q2 2025Quarterly · 2025-04-30GeographyAsia Pacific548,000,000USDDisclosure
    Q2 2025Quarterly · 2025-04-30GeographyEurope442,000,000USDDisclosure
    Q2 2025Quarterly · 2025-04-30ProductInstrumentation550,000,000USDDisclosure
    Q2 2025Quarterly · 2025-04-30ProductNon Instrumentationand Other1,118,000,000USDDisclosure
    Q2 2025Quarterly · 2025-04-30SegmentAgilent Cross Lab713,000,000USDDisclosure
    Q2 2025Quarterly · 2025-04-30SegmentApplied Markets301,000,000USDDisclosure
    Q2 2025Quarterly · 2025-04-30SegmentLife Sciences And Diagnostics Markets654,000,000USDDisclosure
    Q1 2025Quarterly · 2025-01-31GeographyAmericas669,000,000USDDisclosure
    Q1 2025Quarterly · 2025-01-31GeographyAsia Pacific549,000,000USDDisclosure
    Q1 2025Quarterly · 2025-01-31GeographyEurope463,000,000USDDisclosure
    Q1 2025Quarterly · 2025-01-31ProductInstrumentation625,000,000USDDisclosure
    Q1 2025Quarterly · 2025-01-31ProductNon Instrumentationand Other1,056,000,000USDDisclosure
    Q1 2025Quarterly · 2025-01-31SegmentAgilent Cross Lab696,000,000USDDisclosure
    Q1 2025Quarterly · 2025-01-31SegmentApplied Markets338,000,000USDDisclosure
    Q1 2025Quarterly · 2025-01-31SegmentLife Sciences And Diagnostics Markets647,000,000USDDisclosure
    Q4 2024Quarterly · 2024-10-31ProductInstrumentation620,000,000USDDisclosure
    Q4 2024Quarterly · 2024-10-31ProductNon Instrumentationand Other1,081,000,000USDDisclosure
    Q4 2024Quarterly · 2024-10-31SegmentAgilent Cross Lab706,000,000USDDisclosure
    Q4 2024Quarterly · 2024-10-31SegmentApplied Markets338,000,000USDDisclosure
    Q4 2024Quarterly · 2024-10-31SegmentLife Sciences And Diagnostics Markets657,000,000USDDisclosure
    FY 2024Yearly · 2024-10-31ProductInstrumentation2,354,000,000USDDisclosure
    FY 2024Yearly · 2024-10-31ProductNon Instrumentationand Other4,156,000,000USDDisclosure
    FY 2024Yearly · 2024-10-31SegmentAgilent Cross Lab2,747,000,000USDDisclosure
    FY 2024Yearly · 2024-10-31SegmentApplied Markets1,297,000,000USDDisclosure
    FY 2024Yearly · 2024-10-31SegmentLife Sciences And Diagnostics Markets2,466,000,000USDDisclosure
    Q3 2024Quarterly · 2024-07-31GeographyAmericas626,000,000USDDisclosure
    Q3 2024Quarterly · 2024-07-31GeographyAsia Pacific520,000,000USDDisclosure
    Q3 2024Quarterly · 2024-07-31GeographyEurope432,000,000USDDisclosure
    Q3 2024Quarterly · 2024-07-31ProductInstrumentation556,000,000USDDisclosure
    Q3 2024Quarterly · 2024-07-31ProductNon Instrumentationand Other1,022,000,000USDDisclosure
    Q3 2024Quarterly · 2024-07-31SegmentAgilent Cross Lab411,000,000USDDisclosure
    Q3 2024Quarterly · 2024-07-31SegmentDiagnostics And Genomics385,000,000USDDisclosure
    Q3 2024Quarterly · 2024-07-31SegmentLife Sciencesand Applied Markets782,000,000USDDisclosure
    Q2 2024Quarterly · 2024-04-30GeographyAmericas637,000,000USDDisclosure
    Q2 2024Quarterly · 2024-04-30GeographyAsia Pacific510,000,000USDDisclosure
    Q2 2024Quarterly · 2024-04-30GeographyEurope426,000,000USDDisclosure
    Q1 2024Quarterly · 2024-01-31GeographyAmericas630,000,000USDDisclosure
    Q1 2024Quarterly · 2024-01-31GeographyAsia Pacific570,000,000USDDisclosure
    Q1 2024Quarterly · 2024-01-31GeographyEurope458,000,000USDDisclosure
    FY 2023Yearly · 2023-10-31ProductInstrumentation2,742,000,000USDDisclosure
    FY 2023Yearly · 2023-10-31ProductNon Instrumentationand Other4,091,000,000USDDisclosure
    FY 2023Yearly · 2023-10-31SegmentAgilent Cross Lab2,656,000,000USDDisclosure
    FY 2023Yearly · 2023-10-31SegmentApplied Markets1,397,000,000USDDisclosure
    FY 2023Yearly · 2023-10-31SegmentLife Sciences And Diagnostics Markets2,780,000,000USDDisclosure
    FY 2022Yearly · 2022-10-31ProductInstrumentation2,907,000,000USDDisclosure
    FY 2022Yearly · 2022-10-31ProductNon Instrumentationand Other3,941,000,000USDDisclosure
    FY 2022Yearly · 2022-10-31SegmentAgilent Cross Lab1,452,000,000USDDisclosure
    FY 2022Yearly · 2022-10-31SegmentDiagnostics And Genomics1,766,000,000USDDisclosure
    FY 2022Yearly · 2022-10-31SegmentLife Sciencesand Applied Markets3,630,000,000USDDisclosure
    FY 2021Yearly · 2021-10-31ProductInstrumentation2,657,000,000USDDisclosure
    FY 2021Yearly · 2021-10-31ProductNon Instrumentationand Other3,662,000,000USDDisclosure
    FY 2021Yearly · 2021-10-31SegmentAgilent Cross Lab1,360,000,000USDDisclosure
    FY 2021Yearly · 2021-10-31SegmentDiagnostics And Genomics1,296,000,000USDDisclosure
    FY 2021Yearly · 2021-10-31SegmentLife Sciencesand Applied Markets3,663,000,000USDDisclosure
    FY 2020Yearly · 2020-10-31ProductInstrumentation2,249,000,000USDDisclosure
    FY 2020Yearly · 2020-10-31ProductNon Instrumentationand Other3,090,000,000USDDisclosure
    FY 2020Yearly · 2020-10-31SegmentSegment Total — Agilent Cross Lab1,177,000,000USDDisclosure
    FY 2020Yearly · 2020-10-31SegmentSegment Total — Diagnostics And Genomics1,047,000,000USDDisclosure
    FY 2020Yearly · 2020-10-31SegmentSegment Total — Life Sciencesand Applied Markets3,115,000,000USDDisclosure
    FY 2019Yearly · 2019-10-31ProductInstrumentation2,150,000,000USDDisclosure
    FY 2019Yearly · 2019-10-31ProductNon Instrumentationand Other3,013,000,000USDDisclosure
    FY 2019Yearly · 2019-10-31SegmentSegment Total — Agilent Cross Lab1,840,000,000USDDisclosure
    FY 2019Yearly · 2019-10-31SegmentSegment Total — Diagnostics And Genomics1,021,000,000USDDisclosure
    FY 2019Yearly · 2019-10-31SegmentSegment Total — Life Sciencesand Applied Markets2,302,000,000USDDisclosure
    FY 2018Yearly · 2018-10-31ProductProduct3,746,000,000USDDisclosure

    Periods follow company fiscal calendars. Quarterly, annual and year-to-date amounts are shown separately. Missing values are not zero. Data may be delayed, incomplete or corrected; follow the disclosure links to verify figures.